Bradbury Daniel's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Nov 5, 2024
- Accession no.
- 0001447362-24-000172
- Filed
- Nov 5, 2024
- Trade date
- Nov 1, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 9 non-derivative transactions. Open-market sales total $273.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bradbury DanielCIK 0001236397 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2024 | Common Stock | SSaleDisposed | −1,322 | $33.90F2 | −$44,815.8 | 18,746 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −375 | $33.90F2 | −$12,712.5 | 5,325 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −375 | $33.90F2 | −$12,712.5 | 5,325 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −2,686 | $34.92F6 | −$93,795.12 | 16,060 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −763 | $34.92F6 | −$26,643.96 | 4,562 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −763 | $34.92F6 | −$26,643.96 | 4,562 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −1,009 | $35.33F7 | −$35,647.97 | 15,051 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −287 | $35.33F7 | −$10,139.71 | 4,275 | Indirect | |
| Nov 1, 2024 | Common Stock | SSaleDisposed | −287 | $35.33F7 | −$10,139.71 | 4,275 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $33.30 to $34.28, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $34.35 to $35.30, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $35.31 to $35.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.